NCT06883409Recruiting
Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer
Efficiency of Laparoscopic Interval Cytoreductive Surgery After Neoadjuvant Chemotherapy in Patients With Stage III and IV Epithelial Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 26 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- First submitted
- 23 Jan 2025
- Start date
- May 2022
- Primary completion date
- Jun 2024
- Lead sponsor
- Instituto Nacional de Cancerologia de Mexico
- Diseases
- Ovarian cancer
- NCT number
- NCT06883409
What you commit to
- Study type: Interventional
- Planned participants: 33
- From May 2022 to the primary completion date, Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- With unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates \>2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction).
Other
- Partial response with persistence of ascites or pleural effusion.
Who the study is looking for
- Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV
- Partial and complete response to treatment with QTNA after 3-4 cycles, evaluated by PET-CT imaging study, patients that the functional unit decides to incorporate into the project.
- Ca 125 which will have to be less than 200
- ECOG 0 to 2 without medical contraindication to perform surgery (≤ ASA 2 or ≤ Goldman 2).
Age in the registry: 18 years to 80 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto Nacional de Cancerologia Coordinator of this site? Confirm its status | México | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.